

References

I-157

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Hache M, Swoboda KJ, Sethna N, et al. Intrathecal Injections in Children With Spinal Muscular Atrophy; Nusinersen Clinical Trial Experience. *J Child Neuro.* 2016;899-906.
3. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet.* 2016;3017-3026.
4. Ionis Pharmaceuticals, Inc. A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants with Spinal Muscular Atrophy. NLM Identifier:NCT02193074.
5. SPINRAZA™ [package insert]. Cambridge, MA: Biogen Inc. 2016. Revised 06/2019.
6. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N Engl J Med.* 2018;378:625-35.
7. MICROMEDEX®SOLUTIONS Compendia. 2020. Nusinersen.
8. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Nusinersen.
9. Hayes, Inc. Hayes Health Technology Brief. Nusinersen (Spinraza; Biogen) for Spinal Muscular Atrophy). Lansdale, PA: Hayes, Inc.; June, 2018.
10. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. *J Child Neurol.* 2007;22(8):1027-1049.
11. Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. *Proc Natl Acad Sci U S A.* 1999;96(11):6307-6311.
12. Feldkotter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time light Cyclor PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. *Am J Hum Genet.* 2002;70(2):358-368.
13. Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. *Arch Neurol.* 1995;52(5):518-523.
14. Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. *Neurology.* 2014;83(9):810-817.

15. Kaufmann P, McDermott M, Darras B, et al. Observational Study of Spinal Muscular Atrophy Type 2 and 3 Functional Outcomes Over 1 Year. Arch Neurol. 2011;68(6):779-786.
16. De Vivo DC, Topaloglu H, Swoboda K et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study. 2019; 92(15).